Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Selective JAK Inhibitors for Atopic Dermatitis: Important Additions to the Treatment Toolbox
  • CME
  • CE

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.
Jonathan Silverberg, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: August 12, 2020 Expiration: August 11, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Critically evaluate study results from recent trials of AD regarding treatment efficacy and safety
  • Describe how new trial data will affect/change the management of patients with AD

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Jonathan Silverberg, MD

Associate Professor, Dermatology
Director of Clinical Research
Director of  Patch Testing

George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan Silverberg, MD, has disclosed that he has received consulting fees from AbbVie, Arena, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Novartis, Pfizer, RAPT, Regeneron, Sanofi; fees for non-CME services from Regeneron and Sanofi; and funds for research support from Galderma.

Staff

Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi, Inc.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The primary target audience for the activities includes dermatologists, immunologists, nurses, and other healthcare providers who treat patients with moderate to severe AD.

Goal

The goal of this initiative is to provide dermatologists and allergists with data on current and emerging therapies for moderate to severe AD presented at the virtual RAD 2020 and AAD 2020 conferences.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 12, 2020, through August 11, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO

Released: August 11, 2020

Expert-authored commentary on new data in atopic dermatitis treatment from the 2020 AAD and RAD conferences from Clinical Care Options (CCO)

Andrew F. Alexis, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 10, 2020 Expired: August 9, 2021

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue